Eli Lilly and Company (LLY) Stock Analysis & Price Forecast: Navigating the Biotech Giant’s Future
Welcome, fellow investors! Today, we’re diving deep into the world of Eli Lilly and Company (LLY), a true titan in the Drug Manufacturers – General industry with a staggering market capitalization of $949.98 billion. As a financial journalist, I always ask the critical questions: Does LLY’s current stock price truly reflect its value? Is this company poised for future growth, or are there hidden risks lurking beneath the surface?
We’re all looking for smart investments, aren’t we? Whether you’re a long-term holder or a short-term trader, understanding LLY’s position in the market is crucial. Let’s peel back the layers and discover what the data tells us about Eli Lilly and Company stock right now.
LLY Stock: Your Essential Snapshot
Currently, LLY is trading at $1,059.70 as of November 2025. What’s immediately striking is its robust positive momentum; the stock is comfortably trading above both its 50-day and 200-day moving averages. This often signals a healthy, ongoing uptrend for investors.
Looking ahead, analysts project a somewhat stable, yet varied, outlook. The average 1-year price target sits at $1,012.19, which suggests a potential -4.5% change from today’s price. However, don’t let that singular number overshadow the significant volatility at 24.0% annualized. This kind of swing potential suggests that while the long-term trend might be positive, you should be prepared for some notable price fluctuations along the way.
Eli Lilly and Company’s fundamental story is quite compelling. We’ve seen solid revenue growth, with a remarkable 53.90% year-over-year increase. That’s a powerful indicator of a thriving business. Yet, it’s not without its challenges, particularly the intense competition inherent in the pharmaceutical sector.
What You’ll Uncover in This LLY Analysis
I believe in giving you clear, actionable insights, not just a barrage of numbers. Here’s what we’ll explore to help you make an informed decision about LLY:
- Is now the right time to buy LLY stock? Technically, the indicators are leaning “Neutral,” but we need to address the overbought Relative Strength Index (RSI) at 93.7. Fundamentally, we’ll examine growth metrics alongside debt levels to gauge caution.
- Can Eli Lilly’s core operations fuel future growth? We’ll investigate how its key Drug Manufacturers – General segment, coupled with its ability to manage competitive pressures, will define its growth trajectory.
- What are the biggest risks for LLY investors? The company carries a substantial $42.58 billion in debt, a factor that could become a headwind, especially in a rising interest rate environment. Moreover, the pharmaceutical industry is notoriously competitive, with both established giants and innovative new entrants constantly vying for market share.
Forget the jargon-filled reports or overly simplistic “just buy” advice. My goal is to provide you with clear, comprehensive information. Whether you’re a long-term investor or chasing quicker gains, understanding these details is crucial.
So, is Eli Lilly and Company the investment that could add a successful chapter to your financial story, or are there underlying issues to approach with caution? Let’s dive into the data and find out.
Key Metrics and LLY Stock Forecast Summary
Let’s quickly recap some of the most important metrics for LLY and what they mean for its future.
| Metric Category | Metric | Value | Insight |
|---|---|---|---|
| Current Price | Live Market Price | $1,059.70 | As of November 2025 |
| Price Targets & Forecasts | 1-Month Forecast | $1,059.70 | -0.0% change (Model-driven) |
| 1-Year Forecast | $1,107.47 | +4.5% change (Model-driven) | |
| Analyst Mean Target | $1,012.19 | -4.5% change (Wall Street Consensus) | |
| Trend & Momentum | Trend | Bullish | Price > SMA 50/200 |
| RSI (14-day) | 93.7 | Overbought 🔥 | |
| MACD | 3.19 | Bullish Short-Term Trend | |
| Key Technical Levels | Above SMA 50 | ✅ $887.41 | Strong support level |
| Above SMA 200 | ✅ $783.57 | Long-term bullish signal | |
| 52-Week Range | $623.78 – $1,066.65 | Current price near high end | |
| Volatility (30d Ann.) | 24.0% | Moderate price swings expected | |
| Ownership | Institutional Ownership | 83.21% | High confidence from big players |
| Short % of Float | 0.81% | Low bearish bets |
Right now, LLY’s stock is trading at $1,059.70. The technical picture looks quite bullish because the price is holding strong above both its 50-day ($887.41) and 200-day ($783.57) moving averages. This tells us the stock has been building solid momentum recently.
However, here’s a crucial point: the Relative Strength Index (RSI) is at 93.7, which is a clear “Overbought” signal. While the MACD indicator does show a bullish short-term trend, that high RSI suggests we could see some minor pullbacks as the stock cools off before its next potential upward move. It’s a classic case of momentum needing to consolidate.
Over the past year, LLY has traded between $623.78 and $1,066.65. This wide range highlights two things: first, the stock has made a significant recovery from its lows, which is great to see. Second, the current price is quite close to the higher end of that range, meaning dramatic upward swings might be less likely in the immediate future unless some major news hits. Analysts generally expect modest growth, with a 1-year target of $1,107.47 (+4.5%), though the average consensus target is a bit lower at $1,012.19 (-4.5%).
What’s really interesting is the ownership picture. With 83.21% institutional ownership and a very low short interest of just 0.81%, it seems most large investors are betting on LLY’s long-term success. This indicates a general lack of bearish sentiment from the big players.
LLY Price Forecast Chart
While I can’t display live charts here, imagine a visual representation of LLY’s recent average prices, juxtaposed with a forecasted price range (Low, Average, High) derived from advanced modeling. This chart would typically show the Prophet model’s projections for the stock’s trajectory.
Detailed LLY Stock Forecast Table (November 2025 – November 2026)
Let’s dive into the granular details of LLY’s projected price movements for the coming months. Our model suggests an overall price range fluctuating between approximately $878.49 and $1,264.45 over the forecast horizon from November 2025 to November 2026.
What’s notable is that the forecast uncertainty appears relatively steady. The projected price range, which moves from about $1,059.70 at the current time to $988.07 – $1,264.45 by the end of the period, shows consistent bands rather than erratic shifts.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($1,059.70) | Model Signal |
|---|---|---|---|---|---|
| 2025-11 | $1,059.70 | $1,059.70 | $1,059.70 | -0.0% | Hold/Neutral |
| 2025-12 | $878.49 | $951.54 | $1,035.29 | -10.2% | Consider Short |
| 2026-01 | $881.74 | $958.25 | $1,033.74 | -9.6% | Consider Short |
| 2026-02 | $911.25 | $1,004.05 | $1,077.12 | -5.3% | Consider Short |
| 2026-03 | $961.59 | $1,049.83 | $1,131.38 | -0.9% | Hold/Neutral |
| 2026-04 | $953.32 | $1,047.11 | $1,123.80 | -1.2% | Hold/Neutral |
| 2026-05 | $950.96 | $1,039.56 | $1,123.73 | -1.9% | Hold/Neutral |
| 2026-06 | $971.11 | $1,057.60 | $1,195.84 | -0.2% | Hold/Neutral |
| 2026-07 | $996.85 | $1,087.36 | $1,201.82 | 2.6% | Consider Buy |
| 2026-08 | $985.12 | $1,075.84 | $1,215.43 | 1.5% | Hold/Neutral |
| 2026-09 | $963.69 | $1,086.47 | $1,204.91 | 2.5% | Consider Buy |
| 2026-10 | $982.18 | $1,107.47 | $1,251.37 | 4.5% | Consider Buy |
| 2026-11 | $988.07 | $1,125.45 | $1,264.45 | 6.2% | Consider Buy |
It’s crucial to remember that these forecasts are generated by complex models and inherently carry a degree of uncertainty. They can shift significantly with new market data, breaking company news, or broader economic changes. Future prices are never guaranteed, so always factor in this inherent variability.
Eli Lilly and Company Profile: A Healthcare Powerhouse
Eli Lilly and Company is a true leader in the healthcare sector, specifically within the Drug Manufacturers – General industry. With a substantial market capitalization of $949.98 billion and a dedicated workforce of 47,000 employees, it’s clear this is a major player on the global stage.
If you want to learn more directly from the source, you can visit their official website: https://www.lilly.com.
LLY Business Overview: Innovation Across Global Markets
Eli Lilly and Company is at the forefront of discovering, developing, and bringing human pharmaceuticals to markets across the United States, Europe, China, Japan, and many other international regions. Their diverse product portfolio is truly impressive, addressing critical health needs worldwide.
For diabetes, they offer a range of well-known products including Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. What’s more, their recent introduction of Zepbound for obesity is a significant move into a rapidly expanding market.
The company also boasts a robust oncology pipeline with products like Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Beyond these, their immunology and neuroscience offerings include Olumiant for various autoimmune conditions, Taltz for psoriasis and arthritis, Omvoh for ulcerative colitis, Cymbalta for mental health and pain, Ebglyss for severe atopic dermatitis, and Emgality for migraine prevention.
Eli Lilly and Company is also highly strategic when it comes to collaborations. They’ve partnered with major players like Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd and Genentech, Inc., and Biologics, Inc., among others. Notably, their strategic partnerships extend to cutting-edge areas, including collaborations with AdvanCell for targeted alpha therapies in cancer, and a strategic alliance with NVIDIA Corporation, suggesting a forward-looking approach to technology integration in drug discovery. They even have a research collaboration agreement with Insilico Medicine for advanced therapies.
Founded in 1876, Eli Lilly and Company maintains its headquarters in Indianapolis, Indiana. This long history underscores their deep roots and sustained commitment to pharmaceutical innovation.
Total Valuation for Eli Lilly and Company (LLY)
While Eli Lilly and Company is certainly a key player in the Drug Manufacturers – General industry with its $949.98 billion market cap, its enterprise value (EV) is even higher at $982.64 billion. This difference includes $32.66 billion in debt, which is factored into the EV. Investors clearly have confidence in Eli Lilly’s future earnings potential, but it’s important to keep that substantial debt load in mind, especially if interest rates were to climb further.
When we look at the valuation ratios, they paint an interesting picture. With an EV/Revenue (TTM) of 16.52x and an EV/EBITDA (TTM) of 34.17x, Eli Lilly and Company trades at a premium compared to many of its industry peers. This premium valuation is a reflection of the company’s strong market position, innovative pipeline, and powerful brand assets.
However, a high valuation also means there might be less room for error. The upcoming earnings report on October 30, 2025, will be a critical event, showing whether Eli Lilly’s business operations can continue to grow into this valuation. Additionally, the November 14, 2025 ex-dividend date serves as a reminder that the company actively rewards its shareholders while still investing heavily in future growth. Essentially, you’re paying for quality, but quality often comes at a higher price.
| Metric | Value |
|---|---|
| Market Cap | $949.98 B |
| Enterprise Value | $982.64 B |
| EV/Revenue (TTM) | 16.52x |
| EV/EBITDA (TTM) | 34.17x |
| Next Earnings Date | 2025-10-30 |
| Ex-Dividend Date | 2025-11-14 |
LLY Share Statistics: Ownership & Short Interest
When we look at LLY’s share statistics, we see that nearly all of the company’s 895 million shares are publicly available as float. This high float generally means investors can trade the stock without causing significant price shifts due to limited supply. However, it’s always a consideration that the company could issue more shares, potentially diluting the value of existing stock.
Interestingly, executives and major shareholders hold a very small portion of the company, just 0.16%. This might raise questions about how much “skin in the game” insiders truly have if the company faces challenges. On the flip side, institutional ownership is quite substantial, standing at 83.21%. This strong institutional backing often provides a degree of stability and confidence in the stock, as large funds typically conduct extensive due diligence.
Now, let’s talk about short interest. With 6 million shares currently sold short, representing only 0.81% of the float, it suggests that bearish sentiment against Eli Lilly and Company isn’t particularly strong. This low level generally means that short sellers aren’t expressing much concern for the company’s prospects. It’s always wise to monitor changes in short interest, as a sharp increase could signal growing doubt among investors. Conversely, very low short interest during positive news periods can sometimes deter a “short squeeze” from occurring.
| Metric | Value |
|---|---|
| Shares Outstanding | 895 M |
| Implied Shares Outstanding | 896 M |
| Shares Float | 893 M |
| Insider Ownership | 0.16% |
| Institutional Ownership | 83.21% |
| Shares Short | 6 M |
| Short Ratio (Days To Cover) | 1.80x |
| Short % of Float | 0.81% |
| Shares Short (Prior Month) | 8 M |
| Short Date | 2025-10-31 |
LLY Valuation Metrics: A Premium Price Tag
Eli Lilly and Company’s valuation metrics definitely warrant a closer look. Its Trailing P/E ratio stands at 51.82x, while the Forward P/E is 46.77x. These figures clearly reflect a premium valuation, suggesting the market has high expectations for the company’s future earnings growth. While the forward P/E shows a modest improvement, it still indicates that investors are paying a significant price for each dollar of LLY’s earnings.
Furthermore, LLY’s Price/Sales ratio of $15.99 and Price/Book ratio of $39.90 reinforce this premium. These multiples highlight that the company is valued highly relative to its sales and book value, which is typical for a growth-oriented pharmaceutical giant with a strong pipeline. These metrics offer valuable insight into LLY’s current market positioning relative to its intrinsic value.
From an enterprise value perspective, the EV/Revenue ratio of 16.52x suggests a reasonable revenue-based valuation. However, the EV/EBITDA multiple of 34.17x could be seen as potentially stretched. Combined, these valuation metrics provide a comprehensive, albeit high-priced, view of Eli Lilly and Company’s standing in the market.
| Metric | Value |
|---|---|
| Trailing P/E | 51.82x |
| Forward P/E | 46.77x |
| Price/Sales (TTM) | $15.99 |
| Price/Book (MRQ) | $39.90 |
| EV/Revenue (TTM) | 16.52x |
| EV/EBITDA (TTM) | 34.17x |
LLY Financial Health: Robust, Yet Leveraged for Growth
Eli Lilly and Company’s financial health appears quite robust, showcasing several key strengths that investors will appreciate. The company’s Return on Equity (ROE) of 96.47% and Return on Assets (ROA) of 17.60% are impressive, reflecting a highly efficient use of capital. These are the kinds of numbers you often see in fast-growing, well-managed firms.
However, it’s also clear that LLY has taken on a considerable amount of debt to fuel its operations and growth. The Debt/Equity ratio of 1.79x, with $42.58 billion in total debt against $9.91 billion in cash, highlights this leverage. Even with this debt, the company’s ability to generate $16.06 billion in operating cash flow (TTM) is a significant strength, proving that its core business can consistently produce cash.
When we look at liquidity, the Current Ratio of 1.55x and Quick Ratio of 0.72x suggest a solid position. This means LLY is generally well-equipped to cover its short-term liabilities. Furthermore, the $1.40 billion in levered free cash flow indicates that the company can still generate substantial cash for shareholders even after meeting all its financial obligations. Overall, LLY demonstrates strong operational efficiency and cash-generating capabilities, balanced with a strategic use of debt for expansion.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | 96.47% |
| Return on Assets (ROA TTM) | 17.60% |
| Debt/Equity (MRQ) | 1.79x |
| Total Cash (MRQ) | $9.91 B |
| Total Debt (MRQ) | $42.58 B |
| Current Ratio (MRQ) | 1.55x |
| Quick Ratio (MRQ) | 0.72x |
| Operating Cash Flow (TTM) | $16.06 B |
| Levered Free Cash Flow (TTM) | $1.40 B |
LLY Financial Efficiency: Optimizing Operations and Capital
Eli Lilly and Company’s financial efficiency metrics offer a deeper look into how well the company manages its assets and working capital. An Asset Turnover of 0.75x indicates that LLY generates $0.75 in revenue for every dollar of assets it holds. This suggests a moderate level of efficiency in utilizing its asset base, which is fairly typical for capital-intensive pharmaceutical companies.
The Inventory Turnover of 1.11x shows that Eli Lilly sells and replaces its inventory roughly 1.1 times annually, translating to approximately 328.8 Days Inventory Outstanding. This slower turnover might be due to the complex nature of drug manufacturing and the need to maintain diverse product lines. Meanwhile, Receivables Turnover at 5.40x and 67.6 Days Sales Outstanding reflect somewhat slower collection periods for its sales, which is an area that might warrant attention for potential improvement.
On the positive side, the Working Capital Turnover of 13.62x suggests a highly efficient use of short-term assets to support sales. This is supported by a healthy Current Ratio of 1.55x, signaling good liquidity. However, the Cash Conversion Cycle of approximately ~396.4 days (partial) suggests it takes about 13.2 months to convert inventory and receivables into cash. This extended cycle could potentially strain working capital and is a key metric to monitor.
Despite these nuances, Eli Lilly’s Return on Invested Capital (ROIC) stands strong at 38.49%. This indicates excellent capital efficiency, demonstrating how effectively the company generates returns from the capital it has invested. Overall, while Eli Lilly and Company shows strong capital efficiency, there might be opportunities to further boost profitability through improved asset utilization and faster cash conversion. Investors should always compare these figures to industry peers to truly assess its competitive positioning.
| Metric | Value |
|---|---|
| Asset Turnover (TTM) | 0.75x |
| Inventory Turnover (TTM) | 1.11x |
| Receivables Turnover (TTM) | 5.40x |
| Working Capital Turnover (TTM) | 13.62x |
| Current Ratio (MRQ) | 1.55x |
| Days Sales Outstanding | 67.6 |
| Days Inventory Outstanding | 328.8 |
| Cash Conversion Cycle | ~396.4 days (partial) |
| Return on Invested Capital (ROIC TTM) | 38.49% |
LLY Profitability and Growth: Balancing Expansion with Strong Margins
When we analyze Eli Lilly and Company’s margin performance, it’s clear the company has a strong grip on its costs and pricing strategies. The gross margin of 83.03% is exceptionally high, indicating excellent control over production costs. This is a significant competitive advantage in the pharmaceutical industry.
Furthermore, LLY profits very well from its core operations, as evidenced by an impressive operating margin of 48.29%. An EBITDA margin of 48.35% further reinforces that the company is capable of generating robust cash flow from its operations before accounting for financing and tax strategies. All things considered, Eli Lilly manages to retain around $30.99 in net profit for every $100 of revenue it generates over the last twelve months.
The business is growing at an aggressive pace, with quarterly revenue growth (YoY) at 53.90% and earnings growth (YoY) at an astounding 480.40%. This kind of expansion is truly remarkable. However, investors should keep a close eye on whether this rapid pace can be sustained without eroding those stellar profit margins.
LLY’s $28.73 billion in EBITDA and $49.34 billion in gross profit highlight its raw earning power, while the $18.41 billion in net income reveals how effectively it converts that power into bottom-line results. The company appears to be successfully balancing its pursuit of aggressive growth with the critical need to maintain profitability. Despite its healthy gross margins, there’s a notable difference between the company’s gross and net margins (83.03% versus 30.99%). This gap is likely due to significant operating expenses, interest costs, or taxes, which are important areas for investors to monitor closely.
Moving forward, maintaining steady or improving margins will be paramount. LLY needs to continue defending its pricing power and diligently controlling operating costs, as this will be key to sustaining profitability, especially if the current rapid revenue growth eventually moderates.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 30.99% |
| Operating Margin (TTM) | 48.29% | Gross Margin (TTM) | 83.03% |
| EBITDA Margin (TTM) | 48.35% |
| Revenue (TTM) | $59.42 B |
| Quarterly Revenue Growth (YoY) | 53.90% |
| Gross Profit (TTM) | $49.34 B |
| EBITDA (TTM) | $28.73 B |
| Net Income (TTM) | $18.41 B |
| Earnings Growth (YoY) | 480.40% |
Dividends and Shareholder Returns for LLY
Let’s discuss Eli Lilly and Company’s dividend policy and what it means for shareholders. The company currently offers a $6.00 annual dividend per share, which translates to a dividend yield of 0.57%. This means that for every $100 you invest, you’d receive $0.57 in dividends annually. It’s worth noting that this yield is currently below its 5-year average of 1.01%. This could indicate that the stock price has risen significantly, thereby reducing the yield, or that dividend growth hasn’t quite kept pace with its historical trends.
| Metric | Value |
|---|---|
| Dividend Rate | $6.00 |
| Dividend Yield | 0.57% |
| Payout Ratio | 28.42% |
| 5 Year Average Dividend Yield | 1.01% |
| Trailing Dividend Rate | $5.80 |
| Trailing Dividend Yield | 0.01% |
| Ex-Dividend Date | 2025-11-14 |
| Last Split Date | 1997-10-16 |
| Last Split Factor | 2:1 |
Key Observations & Analysis:
- The payout ratio of 28.42% is quite low and conservative. This means LLY uses only about 28% of its earnings to fund its dividends, leaving ample room for future increases or significant reinvestment back into the business for growth.
- The very low trailing yield of 0.01% suggests there might have been a recent dividend initiation or a special, non-recurring payout that skewed this particular metric. It warrants further investigation into the consistency of past dividend payments.
- If you’re looking to receive the next dividend, you must own the stock before the upcoming ex-dividend date of November 14, 2025.
- The last stock split (2:1 in 1997) is quite old and likely doesn’t have much bearing on the current valuation or investment thesis.
Investor Takeaway:
- For Income Investors: The modest yield and low payout ratio suggest that while dividends are safe, they might not be the primary reason to invest in LLY. The focus here would likely be on the potential for future dividend growth rather than immediate high income.
- For Growth Investors: The low payout ratio is a strong signal that a significant portion of earnings is being reinvested into the company. This capital allocation strategy could very well drive future price appreciation, which aligns perfectly with a growth-oriented investment approach.
What to Watch For:
Keep an eye out for any announcements of dividend hikes from Eli Lilly, which could potentially bring the yield closer to its historical average. Also, significant stock price movements will naturally alter the dividend yield, so monitoring overall market performance is always important.
LLY Technical Analysis: Bullish Trend, but Overheated Short-Term
LLY’s stock has been on an impressive run, gaining a solid +13.21% in just 15 days. While this momentum is certainly appealing, several technical indicators suggest we should approach with caution before chasing this rally. Let’s break down what the charts are really telling us and how to strategize our positions.
Trend Strength – Still Bullish
Eli Lilly (LLY) is currently trading above its key moving averages, which unequivocally confirms that the underlying uptrend remains intact. Specifically, the 20-day Simple Moving Average (SMA) at $978.11 is acting as immediate dynamic support.
What This Means for Traders:
As long as LLY maintains its position above the 20-day SMA ($978.11), the bullish momentum could very well continue. However, it’s important to recognize that such a rapid ascent can push the stock far from its averages, increasing the likelihood and risk of a sharp pullback or correction.
Momentum Check – Time to Be Cautious
The Relative Strength Index (RSI) is flashing a strong overbought signal at 93.7. Historically, when the RSI crosses significantly above the 70-75 threshold, we often see a period of consolidation or a pullback before the stock can embark on its next leg up. Despite this, the MACD histogram remains positive, which confirms that the upward momentum is still fundamentally in play for the time being.
Trading Strategy:
- Aggressive traders might consider taking partial profits to lock in recent gains.
- Conservative traders should probably wait for the RSI to cool down and drop below 70 before considering any new long positions.
Bollinger Bands – Testing Key Levels
LLY is currently trading comfortably in the upper half of its Bollinger Bands, specifically between the 20-day SMA and the upper band. This positioning is generally seen as a sign of underlying strength and continued buying interest.
Volume Trends – Checking for Conviction
Trading volume for LLY is currently near its recent average. This provides neutral confirmation of the ongoing price action, meaning there isn’t an overwhelming surge of buyers or sellers to strongly validate the current trend.
Support & Resistance – Your Trading Plan
Understanding key support and resistance levels is fundamental to any trading strategy. Here’s what to watch:
- Resistance: $1,066.65 (Recent High) → A decisive breakout above this level, especially with strong volume, could propel LLY even higher.
- Support: $978.11 (20-day SMA) → If the stock breaks below this immediate support, we could expect a test of the next significant level at $856.42.
Here’s a clear Trading Plan to consider:
- ✅ If LLY holds above $978.11: The bullish trend is likely to continue, with the next target being the recent high of $1,066.65.
- ⚠️ If it breaks below $978.11: Expect a potential dip towards $856.42 as the stock seeks stronger support.
- 🛑 A drop below $856.42: This could trigger a deeper correction, potentially testing the long-term 200-day SMA at $783.57.
Final Verdict – Buy, Hold, or Sell for LLY?
Short-Term Traders: It’s time to be cautious. The RSI is significantly overbought at 93.7, and volume isn’t strong enough to confirm continued rapid ascent. Consider locking in partial profits near $1,066.65 and patiently waiting for a better entry point, perhaps closer to the 20-day SMA ($978.11).
Long-Term Investors: The long-term uptrend for LLY remains valid as long as the price holds above the crucial 200-day SMA ($783.57). A pullback to the 50-day SMA ($887.41) area could present a safer and more attractive buying opportunity for those looking to establish or add to long-term positions.
New Buyers: Avoid chasing this current rally. It’s often better to wait for either a confirmed, high-volume breakout above $1,066.65 or a more conservative entry point during a pullback to the $978.11 area, which would offer a much better risk/reward setup.
Bottom Line: The technical indicators suggest that LLY’s current rally might be running out of short-term steam. While the long-term trend remains firmly bullish, a correction or consolidation phase seems plausible before the stock makes its next significant move. Trade carefully, always waiting for clear confirmation at these key technical levels.
LLY Bollinger Bands Chart
(Imagine a chart showing the Bollinger Bands, illustrating price volatility and potential overbought/oversold conditions for LLY.)
LLY RSI Chart
(Imagine a chart depicting the Relative Strength Index (RSI), clearly showing the current overbought level of 93.7 for LLY.)
LLY MACD Charts
(Imagine a chart displaying the Moving Average Convergence Divergence (MACD) indicator, including the MACD line, signal line, and histogram, confirming the short-term bullish momentum for LLY.)
LLY Historical Price & Volume Chart
(Imagine a chart illustrating Eli Lilly and Company’s historical closing prices and trading volume, with a 20-day average volume overlay, allowing for visual analysis of past performance and liquidity.)
LLY Historical Performance: A Strong Recent Run
Looking back at the last 15 trading days, from November 07, 2025, to November 21, 2025, LLY stock has delivered a robust return of +14.81%. This highlights a period of significant positive momentum. During this time, the stock traded within a range of $899.58 to $1,066.65, with an average daily trading volume of 4,202,013 shares. This consistent volume indicates healthy investor interest throughout this upward move.
Recent LLY Trading Data
Let’s look at the daily breakdown of LLY’s recent trading activity:
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-11-21 | $1,041.00 | $1,066.65 | $1,038.00 | $1,059.70 | 4,263,900 |
| 2025-11-20 | $1,045.50 | $1,057.00 | $1,038.25 | $1,043.29 | 3,135,700 |
| 2025-11-19 | $1,029.64 | $1,055.59 | $1,026.25 | $1,049.60 | 3,571,200 |
| 2025-11-18 | $1,014.01 | $1,040.72 | $1,014.01 | $1,030.05 | 3,430,500 |
| 2025-11-17 | $1,003.72 | $1,032.14 | $998.30 | $1,021.70 | 4,720,000 |
| 2025-11-16 | $1,009.00 | $1,033.62 | $1,007.79 | $1,025.28 | 3,862,300 |
| 2025-11-15 | $1,009.00 | $1,033.62 | $1,007.79 | $1,025.28 | 3,862,300 |
| 2025-11-14 | $1,009.00 | $1,033.62 | $1,007.79 | $1,025.28 | 3,862,300 |
| 2025-11-13 | $1,008.61 | $1,031.44 | $1,008.61 | $1,021.37 | 4,153,600 |
| 2025-11-12 | $991.66 | $1,020.92 | $988.65 | $1,016.29 | 5,185,200 |
| 2025-11-11 | $965.13 | $998.48 | $963.87 | $987.17 | 4,166,400 |
| 2025-11-10 | $938.36 | $980.55 | $937.03 | $965.22 | 5,696,600 |
| 2025-11-09 | $929.80 | $930.63 | $899.58 | $923.01 | 4,373,400 |
| 2025-11-08 | $929.80 | $930.63 | $899.58 | $923.01 | 4,373,400 |
| 2025-11-07 | $929.80 | $930.63 | $899.58 | $923.01 | 4,373,400 |
LLY Stock Price Statistics: Volatility and Momentum
When we zoom out to look at LLY’s price range over the past year, we see a high of $1,066.65 and a low of $623.78. This wide gap tells us that the stock has experienced significant fluctuations, likely driven by market sentiment, company-specific news, or broader sector trends.
Currently, the 50-day moving average at $849.93 is above the 200-day moving average of $802.37. This formation is often referred to as a ‘golden cross,’ and it’s widely considered a bullish signal, indicating positive long-term momentum for the stock.
With a beta of 0.39x, LLY tends to be less volatile than the broader market, moving about 61% less. This lower sensitivity can appeal to investors seeking some degree of stability in their portfolio. However, combined with a moderate 30-day annualized volatility of 24.0%, it’s clear that the stock still experiences frequent price swings. For investors, this means there’s potential for gains, but also an inherent downside risk associated with those movements. These indicators are crucial when you’re deciding on position sizing or precise entry and exit timings, especially if you’re aiming to balance stability with growth exposure within your investment portfolio.
| Metric | Value |
|---|---|
| 52 Week High | $1,066.65 |
| 52 Week Low | $623.78 |
| 50 Day MA | $849.93 |
| 200 Day MA | $802.37 |
| Beta | 0.39x |
| Volatility (30d Ann.) | 24.0% |
LLY Quarterly Earnings Performance: Strong Revenue Growth
Eli Lilly and Company’s recent quarterly performance showcases strong operational results. In the latest reported quarter (2025-Q3), the company posted impressive revenue of $17.60 billion and a net income of $5.58 billion.
Delving deeper into the growth metrics, the quarter-over-quarter revenue change was a healthy +13.1%. Even more striking is the year-over-year revenue growth, which stands at an exceptional +53.9%. This indicates significant expansion and demand for LLY’s products.
Recent Quarterly Results (Last 4 Quarters)
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| 2025-Q3 | $17.60 B | $5.58 B | 6.21x | 82.9% |
| 2025-Q2 | $15.56 B | $5.66 B | 6.29x | 84.3% |
| 2025-Q1 | $12.73 B | $2.76 B | 3.06x | 82.5% |
| 2024-Q4 | $13.53 B | $4.41 B | 4.88x | 82.2% |
Growth Metrics
| Metric | Value |
|---|---|
| QoQ Revenue Growth | +13.1% |
| QoQ Net Income Growth | -1.4% |
| YoY Revenue Growth | +53.9% |
Upcoming LLY Earnings
Investors should mark their calendars: Eli Lilly and Company’s next earnings report is scheduled for October 30, 2025. The associated earnings call will take place on the same day at 07:30 PM ET. These events are often significant catalysts for stock movement, providing fresh insights into the company’s financial health and future outlook.
LLY Short Selling Information: Low Bearish Bets
Currently, there are 6 million shares of LLY that have been sold short. The short ratio, also known as “days to cover,” stands at 1.8x. This means that, based on the stock’s recent average trading volume, it would take approximately two days for all short positions to be covered. A low days-to-cover figure like this suggests that short sellers do not currently have significant influence over the stock’s price, and the risk of a prolonged “short squeeze” (where rapid short covering drives prices up dramatically) is relatively low.
With just 0.81% of the public float sold short, a very small percentage of available shares are being bet against. This indicates a general lack of bearish sentiment among investors. Interestingly, this level has recently decreased from 8 million shares shorted in the prior month, suggesting a further shift away from bearish positions. Because the amount of investors shorting is generally low, the market tends to feel more confident, and the risks of sharp price swings from sudden short-covering activities are significantly reduced.
| Metric | Value |
|---|---|
| Shares Short | 6 M |
| Short Ratio (Days To Cover) | 1.80x |
| Short % of Float | 0.81% |
| Shares Short (Prior Month) | 8 M |
| Short Date | 2025-10-31 |
LLY Risk Analysis: Understanding the Volatility
When considering an investment in Eli Lilly and Company (LLY), it’s crucial to understand its risk profile. The stock demonstrates moderate volatility, with an annualized volatility of 24.4%. This indicates that while price swings are definitely part of LLY’s trading pattern, they are generally within a moderate range compared to some other high-growth sectors.
The Sharpe ratio of 0.81x suggests mixed risk-adjusted returns. A higher Sharpe ratio is generally preferred, indicating better returns for the level of risk taken. Meanwhile, the maximum drawdown of -34.48% is a significant figure, revealing that investors could have experienced a substantial loss during adverse market conditions in the past. This highlights the potential for notable downside risk.
Looking at Value at Risk (VaR), at a 5% confidence level, it shows a potential loss of -2.15% in the worst 5% of scenarios. This gives investors a statistical measure of potential capital at risk over a specific time frame. The Sortino ratio of 1.12x offers another perspective by focusing specifically on downside risk, providing additional insight into performance adjusted only for negative volatility.
Investors should always weigh these quantitative risk metrics against their own personal risk tolerance and overarching investment objectives. Understanding these numbers helps you build a portfolio that aligns with your comfort level for market fluctuations.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 24.4% |
| Value at Risk (5%) | -2.15% |
| Value at Risk (1%) | -4.05% |
| Sharpe Ratio | 0.81x |
| Sortino Ratio | 1.12x |
| Maximum Drawdown | -34.48% |
| Skewness | 0.92x |
| Kurtosis | 18.87x |
LLY Sentiment Analysis: Cautiously Positive Outlook
A deep dive into the current market sentiment for Eli Lilly and Company (LLY) reveals a cautiously positive outlook. The composite sentiment score stands at 0.32x, with a confidence level of 47.0%. This positive sentiment is not derived from a single source but is synthesized from multiple data points, including recent news coverage, professional analyst recommendations, and activity within the options market.
Breaking down these sentiment components offers more clarity:
- News analysis currently shows a positive sentiment score of 0.14x.
- Analyst consensus reflects a more strongly positive sentiment at 0.40x.
- The options market sentiment also mirrors a positive outlook, registering at 0.32x.
These sentiment indicators are valuable tools, but they should always be considered alongside a thorough fundamental and technical analysis to form a truly comprehensive investment perspective. Don’t base your decisions solely on sentiment, but use it as another piece of the puzzle.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.32x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 47.0% |
| News Sentiment | Positive (0.14x) |
| Analyst Sentiment | Positive (0.40x) |
| Options Sentiment | Positive (0.32x) |
| Put/Call Ratio | 0.34x |
LLY Peer Comparison: Standing Out in Pharma
Eli Lilly and Company (LLY) truly stands out among its peers in the pharmaceutical industry. With a colossal market cap of $949.98 billion, it significantly outpaces giants like Johnson & Johnson (JNJ) at $491.26 billion, Merck (MRK) at $244.18 billion, and Pfizer (PFE) at $142.37 billion. This sheer size underscores LLY’s dominant market position.
LLY’s elevated P/E ratio of 51.82x indicates a premium valuation, reflecting strong growth prospects and investor confidence in its innovative pipeline. In contrast, JNJ (P/E 19.68x), MRK (P/E 12.93x), and PFE (P/E 14.56x) trade at much lower multiples, typically reflecting more mature or slower-growth businesses.
The company’s revenue growth is exceptional, with a robust 53.90% expansion, easily outperforming JNJ (6.80%), MRK (3.70%), and PFE (-5.90%). LLY’s strong 30.99% net margin also demonstrates impressive profitability, comparing favorably to JNJ (27.26%) and MRK (29.63%).
Furthermore, LLY’s exceptional 96.47% Return on Equity (ROE) indicates highly efficient use of shareholder equity, far surpassing its competitors. While carrying a debt-to-equity ratio of 179, LLY maintains moderate leverage within the industry. Finally, LLY offers a substantial 57.00% dividend yield, providing significant income to shareholders, compared to JNJ (2.55%) and MRK (3.48%).
This comparison clearly positions Eli Lilly as a leader in growth, profitability, and shareholder returns within its sector.
| Metric | LLY | JNJ | MRK | PFE |
|---|---|---|---|---|
| Market Cap | $949.98 B | $491.26 B | $244.18 B | $142.37 B |
| P/E Ratio | 51.82 | 19.68 | 12.93 | 14.56 |
| Revenue Growth | 53.90% | 6.80% | 3.70% | -5.90% |
| Net Margin | 30.99% | 27.26% | 29.63% | 15.65% |
| EPS | 20.45 | 10.36 | 7.56 | 1.72 |
| ROE | 96.47% | 33.62% | 39.49% | 10.60% |
| Debt-to-Equity | 179 | 57.77 | 79.71 | 66.53 |
| Dividend Yield | 57.00% | 2.55% | 3.48% | 6.87% |
| 52-Week Range | 621.50 – 1066.65 | 137.37 – 206.94 | 71.87 – 101.32 | 19.83 – 27.21 |
LLY Insider Transactions (Last 3 Months): A Bearish Signal
The insider transaction data for Eli Lilly and Company over the last three months reveals a notably bearish trend. We’ve seen a significant imbalance: 277 insider sells compared to just 26 buys, totaling a substantial $78.5 billion in net sales. This pattern suggests that insiders, who typically have the most intimate knowledge of the company’s operations, are actively reducing their exposure.
Focusing specifically on discretionary open-market activity, the trend is even clearer. There were 274 market sales with zero market purchases, indicating a deliberate decision by insiders to offload shares. Price analysis further supports this, showing that sales generally occurred at elevated levels, averaging $8419.10 across 274 priced transactions. In contrast, the few purchases averaged $917.13 across 26 transactions, suggesting these might be less significant or related to specific compensation events rather than large-scale conviction buys.
The ongoing market transactions continue to lean heavily toward selling, with insiders persistently reducing their positions in the near term. The sheer scale of this discretionary market selling activity should certainly give investors pause. When individuals with the best visibility into a company’s inner workings are actively reducing their holdings, it warrants a careful re-evaluation of the near-term risk/reward dynamics for LLY stock.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,206 | $1055.08 | 92,644,452 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,109 | $1054.48 | 92,645,658 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,820 | $1053.47 | 92,651,767 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -21,107 | $1052.54 | 92,665,587 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -28,768 | $1051.43 | 92,686,694 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -96,516 | $1050.21 | 92,715,462 | 2025-11-19 | 2025-11-20 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -980 | $1039.61 | 92,811,978 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,950 | $1038.48 | 92,812,958 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,424 | $1037.38 | 92,816,908 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,067 | $1036.58 | 92,819,332 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,097 | $1035.50 | 92,827,399 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,198 | $1034.65 | 92,840,496 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,380 | $1033.50 | 92,852,694 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,208 | $1032.63 | 92,859,074 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,605 | $1031.41 | 92,866,282 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,304 | $1030.32 | 92,867,887 | 2025-11-18 | 2025-11-19 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,097 | $1031.53 | 92,872,191 | 2025-11-17 | 2025-11-18 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,789 | $1030.45 | 92,874,288 | 2025-11-17 | 2025-11-18 |
| JOHNSON KIMBERLY H | BUY (Award) [A] | +215 | $1021.70 | 3,265 | 2025-11-17 | 2025-11-18 |
| JACKSON JAMERE | BUY (Award) [A] | +215 | $1021.70 | 9,635 | 2025-11-17 | 2025-11-18 |
| Kaelin William G Jr | BUY (Award) [A] | +215 | $1021.70 | 21,837 | 2025-11-17 | 2025-11-18 |
| Baicker Katherine | BUY (Award) [A] | +215 | $1021.70 | 23,503 | 2025-11-17 | 2025-11-18 |
| LUCIANO JUAN R | BUY (Award) [A] | +215 | $1021.70 | 16,704 | 2025-11-17 | 2025-11-18 |
| LUCIANO JUAN R | BUY (Award) [A] | +15 | $1021.70 | 16,489 | 2025-11-17 | 2025-11-18 |
| Moeller Jon R | BUY (Award) [A] | +233 | $1021.70 | 304 | 2025-11-17 | 2025-11-18 |
| Fyrwald J Erik | BUY (Award) [A] | +215 | $1021.70 | 74,989 | 2025-11-17 | 2025-11-18 |
| Fyrwald J Erik | BUY (Award) [A] | +10 | $1021.70 | 74,773 | 2025-11-17 | 2025-11-18 |
| Hedley Mary Lynne | BUY (Award) [A] | +215 | $1021.70 | 2,241 | 2025-11-17 | 2025-11-18 |
| Hedley Mary Lynne | BUY (Award) [A] | +10 | $1021.70 | 2,026 | 2025-11-17 | 2025-11-18 |
| Alvarez Ralph | BUY (Award) [A] | +215 | $1021.70 | 55,379 | 2025-11-17 | 2025-11-18 |
| Alvarez Ralph | BUY (Award) [A] | +12 | $1021.70 | 55,163 | 2025-11-17 | 2025-11-18 |
| Sulzberger Gabrielle | BUY (Award) [A] | +215 | $1021.70 | 2,948 | 2025-11-17 | 2025-11-18 |
| Sulzberger Gabrielle | BUY (Award) [A] | +5 | $1021.70 | 2,733 | 2025-11-17 | 2025-11-18 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -949 | $1033.15 | 92,882,077 | 2025-11-14 | 2025-11-17 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -17,567 | $1032319.00 | 92,883,026 | 2025-11-14 | 2025-11-17 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -55,908 | $1031414.00 | 92,900,593 | 2025-11-14 | 2025-11-17 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -103,871 | $1030.31 | 92,956,501 | 2025-11-14 | 2025-11-17 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,360 | $1031.78 | 93,060,372 | 2025-11-13 | 2025-11-14 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -45,246 | $1030.21 | 93,061,732 | 2025-11-13 | 2025-11-14 |
| Zakrowski Donald A | SELL (Sale) [S] | -1,000 | $1010.50 | 2,840 | 2025-11-13 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -842 | $1021.07 | 93,106,978 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,281 | $1019.92 | 93,107,820 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,833 | $1018.83 | 93,109,101 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -47,073 | $1018.02 | 93,116,934 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,188 | $1017.16 | 93,164,007 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,415 | $1016.00 | 93,171,195 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -16,274 | $1015.16 | 93,184,610 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,638 | $1014.17 | 93,200,884 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -16,749 | $1012.94 | 93,212,522 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -21,559 | $1011.96 | 93,229,271 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -19,892 | $1011.18 | 93,250,830 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -20,000 | $1009.99 | 93,270,722 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -17,985 | $1009.00 | 93,290,722 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,913 | $1007.97 | 93,308,707 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -16,383 | $1007.10 | 93,317,620 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -23,863 | $1006.02 | 93,334,003 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -23,568 | $1004.97 | 93,357,866 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -22,131 | $1004.10 | 93,381,434 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,585 | $1003.12 | 93,403,565 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -828 | $1001.93 | 93,411,150 | 2025-11-12 | 2025-11-13 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,384 | $999.09 | 93,411,978 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,482 | $998.29 | 93,415,362 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -9,387 | $997.06 | 93,420,844 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,039 | $996.38 | 93,430,231 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,664 | $995.25 | 93,442,270 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,022 | $994.12 | 93,446,934 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -9,879 | $993.10 | 93,451,956 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -9,369 | $992.01 | 93,461,835 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -26,761 | $991.01 | 93,471,204 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -33,154 | $990.19 | 93,497,965 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -22,127 | $989.18 | 93,531,119 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,473 | $987.91 | 93,553,246 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,678 | $987.18 | 93,557,719 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -30,633 | $986.18 | 93,571,397 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,877 | $985.25 | 93,602,030 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,066 | $984.04 | 93,610,907 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,503 | $983.14 | 93,621,973 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,211 | $981.85 | 93,629,476 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,068 | $980.54 | 93,631,687 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,555 | $979.65 | 93,633,755 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,433 | $978.69 | 93,637,310 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,680 | $977.44 | 93,641,743 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,759 | $976.49 | 93,646,423 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,996 | $975.46 | 93,652,182 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,114 | $974.47 | 93,661,178 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,998 | $973.48 | 93,671,292 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,819 | $972.27 | 93,683,290 | 2025-11-11 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -118 | $974.09 | 93,695,109 | 2025-11-10 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,887 | $973.63 | 93,695,227 | 2025-11-10 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,864 | $972.17 | 93,699,114 | 2025-11-10 | 2025-11-12 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,110 | $954.95 | 93,711,978 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,699 | $953.66 | 93,713,088 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,392 | $952.89 | 93,717,787 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,200 | $952.00 | 93,728,179 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,010 | $950.94 | 93,738,379 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,495 | $949.82 | 93,740,389 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,617 | $948.82 | 93,744,884 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,909 | $947.63 | 93,750,501 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,773 | $946.40 | 93,752,410 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,007 | $945.62 | 93,756,183 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,581 | $944.68 | 93,769,190 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,820 | $943.71 | 93,781,771 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,657 | $942.31 | 93,785,591 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,759 | $941.36 | 93,787,248 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,966 | $940.62 | 93,790,007 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,790 | $939.54 | 93,793,973 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,388 | $938.43 | 93,796,763 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,731 | $937.42 | 93,800,151 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,292 | $936.57 | 93,803,882 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,386 | $935.26 | 93,809,174 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -9,209 | $934.21 | 93,815,560 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,642 | $933.29 | 93,824,769 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,924 | $932.27 | 93,831,411 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,938 | $931.25 | 93,844,335 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,528 | $930.22 | 93,855,273 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -15,230 | $929.42 | 93,860,801 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,457 | $928.20 | 93,876,031 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,409 | $927.12 | 93,880,488 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -31,016 | $925.87 | 93,888,897 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -550 | $924.35 | 93,919,913 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,635 | $923.46 | 93,920,463 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,434 | $922.42 | 93,923,098 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,090 | $921.50 | 93,927,532 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -160 | $918.12 | 93,929,622 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -230 | $917.26 | 93,929,782 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -550 | $915.33 | 93,930,012 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -620 | $913.78 | 93,930,562 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -270 | $911.00 | 93,931,182 | 2025-11-05 | 2025-11-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -526 | $910.72 | 93,931,452 | 2025-11-04 | 2025-11-05 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,633 | $900.79 | 93,931,978 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,474 | $900.02 | 93,933,611 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,391 | $899.18 | 93,938,085 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -19,295 | $898.20 | 93,943,476 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,842 | $897.20 | 93,962,771 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -29,709 | $896.15 | 93,974,613 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -17,639 | $895.15 | 94,004,322 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -17,537 | $894.33 | 94,021,961 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,246 | $893.35 | 94,039,498 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -17,299 | $891.97 | 94,043,744 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -15,508 | $891.17 | 94,061,043 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -14,867 | $890.20 | 94,076,551 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,452 | $888.96 | 94,091,418 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,081 | $888.14 | 94,093,870 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,038 | $886.29 | 94,097,951 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -21,884 | $885.56 | 94,100,989 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -26,340 | $884.66 | 94,122,873 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,681 | $883.75 | 94,149,213 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,226 | $882.32 | 94,159,894 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,373 | $881.46 | 94,164,120 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,549 | $880.45 | 94,170,493 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -6,125 | $879.36 | 94,181,042 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -18,815 | $878.36 | 94,187,167 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -25,996 | $877.40 | 94,205,982 | 2025-11-03 | 2025-11-04 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,910 | $869.47 | 94,231,978 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -5,440 | $868.44 | 94,234,888 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,602 | $867.54 | 94,240,328 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,358 | $866.55 | 94,244,930 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,356 | $865.60 | 94,255,288 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -15,671 | $864.53 | 94,265,644 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -54,191 | $863.42 | 94,281,315 | 2025-10-31 | 2025-11-03 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -197,814 | $862.63 | 94,335,506 | 2025-10-31 | 2025-11-03 |
| LUCIANO JUAN R | BUY (Award) [A] | +18 | $808.96 | 16,474 | 2025-10-20 | 2025-10-22 |
| Fyrwald J Erik | BUY (Award) [A] | +12 | $808.96 | 74,764 | 2025-10-20 | 2025-10-22 |
| Hedley Mary Lynne | BUY (Award) [A] | +12 | $808.96 | 2,016 | 2025-10-20 | 2025-10-22 |
| Alvarez Ralph | BUY (Award) [A] | +15 | $808.96 | 55,152 | 2025-10-20 | 2025-10-22 |
| Sulzberger Gabrielle | BUY (Award) [A] | +6 | $808.96 | 2,728 | 2025-10-20 | 2025-10-22 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,190 | $863.37 | 94,533,320 | 2025-10-10 | 2025-10-14 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -468 | $862.34 | 94,536,510 | 2025-10-10 | 2025-10-14 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -200 | $857.25 | 94,536,978 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -835 | $854.96 | 94,537,178 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,473 | $854.61 | 94,538,013 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -1,247 | $853.20 | 94,539,486 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,472 | $852.21 | 94,540,733 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,375 | $851.58 | 94,543,205 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -400 | $850.05 | 94,546,580 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -600 | $848.63 | 94,546,980 | 2025-10-09 | 2025-10-10 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -200 | $856.00 | 94,547,580 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -946 | $854.64 | 94,547,780 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,881 | $853.85 | 94,548,726 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,227 | $852.36 | 94,552,607 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -13,624 | $851.40 | 94,555,834 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -36,114 | $850.52 | 94,569,458 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -25,296 | $849.60 | 94,605,572 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -18,132 | $848.46 | 94,630,868 | 2025-10-08 | 2025-10-09 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -26,795 | $848.01 | 94,649,000 | 2025-10-07 | 2025-10-08 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,399 | $855.71 | 94,675,795 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,143 | $854.54 | 94,678,194 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -14,822 | $853.64 | 94,685,337 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -9,767 | $852.67 | 94,700,159 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -12,180 | $851.58 | 94,709,926 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -22,960 | $850.65 | 94,722,106 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -28,063 | $849.44 | 94,745,066 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -63,849 | $848.30 | 94,773,129 | 2025-10-06 | 2025-10-07 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -405 | $847.60 | 94,836,978 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -4,870 | $847.03 | 94,837,383 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,893 | $845.82 | 94,842,253 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,135 | $845.07 | 94,846,146 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,114 | $843.64 | 94,856,281 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -10,040 | $842.95 | 94,863,395 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -11,316 | $841.70 | 94,873,435 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -24,495 | $840.74 | 94,884,751 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -31,102 | $839.94 | 94,909,246 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -7,894 | $838.86 | 94,940,348 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -22,843 | $837.78 | 94,948,242 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -16,792 | $836.86 | 94,971,085 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -8,203 | $835.77 | 94,987,877 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -3,509 | $834.76 | 94,996,080 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -2,204 | $833.83 | 94,999,589 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -300 | $831.05 | 95,001,793 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -872 | $829.86 | 95,002,093 | 2025-10-03 | 2025-10-06 |
| LILLY ENDOWMENT INC | SELL (Sale) [S] | -200 | $828.50 | 95,002,965 | 2025-10-03 | 2025-10-0 |
Pingback: Oracle Corporation (ORCL) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia
Pingback: Exxon Mobil Corporation (XOM) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia
Pingback: Mastercard Incorporated (MA) Stock Analysis: Price Forecast, Technicals & Investment Outlook - Stockdunia
Pingback: Johnson & Johnson (JNJ) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia
Pingback: Accenture plc (ACN) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia
Pingback: ChargePoint Holdings, Inc. (CHPT) Stock Analysis: Price Forecast, Technicals & Investment Outlook - Stockdunia